Ko143 hydrate
SIGMA/K2144 - ≥98% (HPLC)
Synonym: (3S,6S,12aS)
CAS Number: 461054-93-3 (anhydrous)
Empirical Formula (Hill Notation): C26H35N3O5 · xH2O
Molecular Weight: 469.57 (anhydrous basis)
MDL Number: MFCD19053160
Linear Formula: C26H35N3O5 · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C26H35N3O5.H2O/c1-14(2 |
| InChI key | ZXXZDXPNJJZRDC-PSLBYKFTSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | O.COc1ccc2c3C[C@@H]4N([C@ |
| solubility | DMSO: >10 mg/mL |
| storage temp. | room temp |
| Application: | Ko143 hydrate has been used: • to determine the role of ATP-binding cassette sub-family G member 2 (ABCG2), human embryonic kidney (HEK)-C1 and HEK-ABCG2 in tumor microenvironment • to inhibit ABCG2 for sphere formation assay • in calcein-AM efflux inhibition to monitor multidrug resistance protein (MRP)-function in kidney • for cell viability assay |
| Biochem/physiol Actions: | Ko143 has been used as a positive control inhibitor on functions of BCRP in MCF7 and BCRP over-expressing MCF7/MX100 cell lines using a BCRP prototypical substrate mitoxantrone. |
| Biochem/physiol Actions: | Ko143 has been used as a positive control inhibitor on functions of BCRP in MCF7 and BCRP over-expressing MCF7/MX100 cell lines using a BCRP prototypical substrate mitoxantrone. The ABCG2 transporter breast cancer resistance protein (BCRP) plays an important role in disposition of many drugs and environmental toxins. Ko143 displays > 200-fold selectivity over P-gp and MRP-1 transporters. It increases intracellular drug accumulation and reverse BCRP-mediated multidrug resistance. It blocked topotecan and ABZSO transport in a concentration-dependent manner. Ko143 is reported to be a more specific inhibitor of BCRP than other known inhibitors of BCRP such as fumitremorgin C and GF120918. |
| Biochem/physiol Actions: | Ko143 has been used as a positive control inhibitor on functions of breast cancer resistance protein (BCRP) using a BCRP prototypical substrate mitoxantrone. |
| Biochem/physiol Actions: | Ko143 has been used as a positive control inhibitor on functions of breast cancer resistance protein (BCRP) using a BCRP prototypical substrate mitoxantrone. BCRP, an ABCG2 transporter, plays an important role in disposition of many drugs and environmental toxins. Ko143 displays > 200-fold selectivity over P-gp and MRP-1 transporters and thus is more specific than other known BCRP inhibitors such as fumitremorgin C and GF120918. It increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance. It blocks topotecan and ABZSO transport in a concentration-dependent manner. |
| Features and Benefits: | This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 1, 5 mg in glass bottle |
| Preparation Note: | The stability of this product in solution has not been determined. According to various sources this product can be stored in solvent (DMSO) at -80°C for 6 months and -20°C for 1 month. |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P261 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |


